The White House’s release of its Artificial Intelligence (AI) Action Plan last month mentions “healthcare” several times, one of the few industries specifically called out. There’s a reason: Healthcare and life sciences are about to face unprecedented AI-driven regulatory changes that will reshape everything from research and development to drug approval submissions.

The Food & Drug Association (FDA) already signaled a transition to AI-enabled infrastructure and support capabilities through its Elsa announcement earlier this year. With the addition of the AI Action Plan, it is evident that government agencies and regulatory bodies will continue to explore AI-enabled oversight. As healthcare and life sciences organizations prepare for continued adjustments to regulatory expectations, s

See Full Page